VTN and autoimmune polyendocrinopathy: In mice, genetic deletion of complement factors or the use of drugs targeting specific complement proteins prevented obstetric and thrombotic complications induced by passive transfer of antiphospholipid antibodies from APS patients, including foetal loss, growth retardation, thrombosis or glomerular TMA [91–98].